Good annual results confirm Onxeo’s strategy
​Onxeo's 2014 annual results confirmed the successful integration of Danish Topotarget and the relevance of this strategic acquisition in the field of orphan oncology. The merger allowed the company to generate more than €35M in revenue for 2014 (pro forma), and a net profit of €7.3M if non-recurring expenses are excluded. The company has 3 products in late stage development. Beleodaq milestone payments and the December 2014 offering, gave Onxeo enough cash to fund its operation for 2 years. This will allow Onxeo to accelerate the recruitment of Livatag's phase III trial, to initiate Validive's phase III, and to continue the development of Belinostat in PTCL as well as in other rare cancers. We adjusted our valuation (including cash) to €10.03/share.​
Onxeo is a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, driven by high therapeutic demand in one of the fastest growing segments of the pharmaceutical industry. Co.'s orphan oncology product portfolio comprises 3 products (Livatag®, Beleodaq®, and AsiDNA™), ranging from preclinical to advanced phases of clinical development.
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.